Charles River Laboratories International, Inc.
CRL
$163.71
-$0.40-0.24%
NYSE
| 06/28/2025 | 03/29/2025 | 12/28/2024 | 09/28/2024 | 06/29/2024 | |
|---|---|---|---|---|---|
| Net Income | -67.04M | -19.66M | 22.20M | 423.78M | 441.51M |
| Total Depreciation and Amortization | 420.77M | 351.85M | 352.34M | 340.15M | 330.82M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 392.18M | 425.15M | 390.36M | -18.23M | -3.79M |
| Change in Net Operating Assets | 41.55M | 19.05M | -30.33M | 50.46M | -18.73M |
| Cash from Operations | 787.45M | 776.39M | 734.58M | 796.16M | 749.82M |
| Capital Expenditure | -208.96M | -213.15M | -232.97M | -235.67M | -262.90M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 0.00 | -5.48M | -5.48M | -150.10M | -150.10M |
| Divestitures | 17.44M | 17.44M | -- | -- | -- |
| Other Investing Activities | 11.27M | -3.59M | -6.64M | -21.58M | -52.59M |
| Cash from Investing | -180.25M | -204.77M | -245.09M | -407.35M | -465.59M |
| Total Debt Issued | 1.30B | 1.20B | 1.08B | 1.42B | 1.24B |
| Total Debt Repaid | -1.39B | -1.35B | -1.49B | -1.64B | -1.52B |
| Issuance of Common Stock | 1.55M | 2.37M | 23.88M | 29.05M | 32.21M |
| Repurchase of Common Stock | -461.39M | -462.96M | -119.18M | -119.19M | -18.44M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -65.43M | -60.37M | -43.44M | -43.68M | -34.36M |
| Cash from Financing | -615.66M | -674.60M | -550.93M | -351.48M | -306.81M |
| Foreign Exchange rate Adjustments | 12.19M | -3.82M | -17.47M | 8.70M | -5.19M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3.74M | -106.81M | -78.91M | 46.02M | -27.77M |